Sysmex Corporation is engaged in the development, manufacture, import, export and sale of clinical laboratory instruments, reagents and software used in -vitro diagnostics. It also provides clinical laboratory testing of blood, urine and other specimens. The company's product includes instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis and point-of-care testing. Its operating segment consists of Japan, Americas, EMEA, China and Asia Pacific. Sysmex Corporation is headquartered in Kobe, Japan.
Revenue (Most Recent Fiscal Year) | $3.34B |
Net Income (Most Recent Fiscal Year) | $354.21M |
PE Ratio (Current Year Earnings Estimate) | 20.35 |
PE Ratio (Trailing 12 Months) | 25.64 |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 2.40 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.53 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 13.17 |
Pre-Tax Margin (Trailing 12 Months) | 15.57% |
Net Margin (Trailing 12 Months) | 9.35% |
Return on Equity (Trailing 12 Months) | 10.20% |
Return on Assets (Trailing 12 Months) | 7.25% |
Current Ratio (Most Recent Fiscal Quarter) | 3.37 |
Quick Ratio (Most Recent Fiscal Quarter) | 2.30 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.12 |
Inventory Turnover (Trailing 12 Months) | 2.77 |
Book Value per Share (Most Recent Fiscal Quarter) | $5.06 |
Earnings per Share (Most Recent Fiscal Quarter) | $0.05 |
Earnings per Share (Most Recent Fiscal Year) | $0.57 |
Diluted Earnings per Share (Trailing 12 Months) | $0.50 |
Exchange | -- |
Sector | -- |
Industry | -- |
Common Shares Outstanding | 629.48M |
Free Float | -- |
Market Capitalization | $8.07B |
Average Volume (Last 20 Days) | 0.11M |
Beta (Past 60 Months) | 1.15 |
Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
Annual Dividend (Based on Last Quarter) | $0.16 |
Dividend Yield (Based on Last Quarter) | 1.24% |